Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Phase 2 Completed 52 enrolled FORUM Pharmaceuticals Inc Parexel · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or early Alzheimer's disease.

Timeline

Start: 2012-11
Primary completion: 2013-10
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVP-0962	Unknown	10 mg	Oral
Subject	EVP-0962	Unknown	50 mg	Oral
Subject	EVP-0962	Unknown	100 mg	Oral
Subject	EVP-0962	Unknown	200 mg	Oral

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Summary

Timeline

Drugs

Indications